Amoy Diagnostics Co., Ltd. (300685.SZ)
CNY 20.9
(-0.9%)
CNY 20.9
(-0.9%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 221.04 Million CNY | 46.2% |
| 2022 | 151.19 Million CNY | 0.63% |
| 2021 | 150.25 Million CNY | -8.61% |
| 2020 | 164.4 Million CNY | 13.64% |
| 2019 | 144.66 Million CNY | 133.31% |
| 2018 | 62 Million CNY | 35.84% |
| 2017 | 45.64 Million CNY | 0.55% |
| 2016 | 45.39 Million CNY | -16.78% |
| 2015 | 54.54 Million CNY | -38.65% |
| 2014 | 88.9 Million CNY | 25.13% |
| 2013 | 71.05 Million CNY | 43.24% |
| 2012 | 49.6 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 227.13 Million CNY | 5.3% |
| 2024 Q2 | 215.7 Million CNY | 6.38% |
| 2024 Q1 | 202.77 Million CNY | -8.26% |
| 2023 Q3 | 161.23 Million CNY | 6.32% |
| 2023 Q4 | 221.04 Million CNY | 37.09% |
| 2023 FY | 221.04 Million CNY | 46.2% |
| 2023 Q1 | 126.69 Million CNY | -16.21% |
| 2023 Q2 | 151.65 Million CNY | 19.7% |
| 2022 Q4 | 151.19 Million CNY | 0.98% |
| 2022 Q1 | 124.17 Million CNY | -17.36% |
| 2022 Q2 | 148.93 Million CNY | 19.94% |
| 2022 FY | 151.19 Million CNY | 0.63% |
| 2022 Q3 | 149.73 Million CNY | 0.54% |
| 2021 Q3 | 123.93 Million CNY | -0.06% |
| 2021 FY | 150.25 Million CNY | -8.61% |
| 2021 Q1 | 166.29 Million CNY | 1.15% |
| 2021 Q2 | 124 Million CNY | -25.43% |
| 2021 Q4 | 150.25 Million CNY | 21.24% |
| 2020 Q3 | 169.52 Million CNY | -12.8% |
| 2020 FY | 164.4 Million CNY | 13.64% |
| 2020 Q2 | 194.4 Million CNY | 11.53% |
| 2020 Q1 | 174.31 Million CNY | 20.49% |
| 2020 Q4 | 164.4 Million CNY | -3.02% |
| 2019 Q2 | 132.24 Million CNY | 176.74% |
| 2019 Q3 | 144.11 Million CNY | 8.98% |
| 2019 Q1 | 47.78 Million CNY | -22.94% |
| 2019 Q4 | 144.66 Million CNY | 0.38% |
| 2019 FY | 144.66 Million CNY | 133.31% |
| 2018 Q1 | 42.1 Million CNY | -7.75% |
| 2018 FY | 62 Million CNY | 35.84% |
| 2018 Q4 | 62 Million CNY | -33.85% |
| 2018 Q2 | 60.15 Million CNY | 42.84% |
| 2018 Q3 | 93.73 Million CNY | 55.84% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q3 | 56.39 Million CNY | 14.81% |
| 2017 Q4 | 45.64 Million CNY | -19.06% |
| 2017 FY | 45.64 Million CNY | 0.55% |
| 2017 Q2 | 49.12 Million CNY | 0.0% |
| 2016 FY | 45.39 Million CNY | -16.78% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q4 | 45.39 Million CNY | 0.0% |
| 2015 Q4 | 54.54 Million CNY | 0.0% |
| 2015 FY | 54.54 Million CNY | -38.65% |
| 2015 Q2 | 48.31 Million CNY | 19.39% |
| 2015 Q1 | 40.46 Million CNY | 0.0% |
| 2014 FY | 88.9 Million CNY | 25.13% |
| 2013 FY | 71.05 Million CNY | 43.24% |
| 2012 FY | 49.6 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 8.02 Billion CNY | 97.245% |
| Hangzhou Tigermed Consulting Co., Ltd. | 5.22 Billion CNY | 95.773% |
| Dirui Industrial Co.,Ltd. | 1.26 Billion CNY | 82.493% |
| Beijing Strong Biotechnologies, Inc. | 1.45 Billion CNY | 84.8% |
| Medicalsystem Biotechnology Co., Ltd. | 772.59 Million CNY | 71.389% |
| Maccura Biotechnology Co.Ltd | 1.5 Billion CNY | 85.34% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.15 Billion CNY | 80.897% |
| Guangdong Hybribio Biotech Co.,Ltd. | 615.23 Million CNY | 64.072% |
| BGI Genomics Co., Ltd. | 3.6 Billion CNY | 93.875% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1 Billion CNY | 78.043% |